RECENT FUNDING
  1. Recent Funding
  2. Investors
  3. Dexcel Pharma
D

Dexcel Pharma portfolio

Dexcel Pharma has 2 portfolio companies on record at Recent Funding, with 1 investment in the last 12 months. It led 2 of the 2 rounds it joined. Its most recent investment on record is Syremis Therapeutics's $165M Series A round in December 2025, which it led, alongside Third Rock Ventures, QVT Financial, Pictet Private Equity Investors S.A. and 2 others. By category, its portfolio leans toward Health and bio (2) and Data and analytics (1). It has co-invested with GV, Bain Capital Life Sciences and Third Rock Ventures.

Type: Investor.
Portfolio on Recent Funding: 2.
Deals, last 12 months: 1.
Rounds led: 2 of 2.
Capital in their rounds: $225M.
Latest deal: Syremis Therapeutics · Dec 18, 2025.

What Dexcel Pharma invests in

How Dexcel Pharma invests

StageDealsCapital in rounds
Series A 2 100%$225M
YearDealsCapital in rounds
2021 1 50%$60M
2025 1 50%$165M

Share is of the 2 rounds on Recent Funding that name Dexcel Pharma. Rounds with no announced date are left out of the year split, and "round" is a round whose stage is not on file.

Dexcel Pharma portfolio companies

CompanyRound with Dexcel PharmaTotal raisedLatest raise
SSyremis Therapeutics
Health and bio
 Series A · $165M · lead$165MDec 18, 2025
Series A
IImmunai
Health and bio
 Series A · $60M · lead$295MOct 28, 2021
Series B+

Most frequent co-investors

Similar investors

Investors whose portfolios on Recent Funding center on the same category (Health and bio).

Portfolio companies are the companies on Recent Funding with a round that lists Dexcel Pharma, which is a subset of its real portfolio. API: /api/v1/investors/dexcel-pharma (get a free API key). More: the most active VC firms and new venture capital funds.